1
Kevin Rodzinak
Donna J Armstrong, Essa H Hu, Michael J Kelly III, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Michael J Rossi, Philip E Sanderson, Jiabing Wang: Inhibitors of akt activtiy. Merck Sharp & Dohme, Matthew A Leff, David A Mutard, August 30, 2011: US08008317 (4 worldwide citation)

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


2
Kevin Rodzinak
Philip E Sanderson, Mark E Layton, Kevin J Rodzinak: Inhibitors of AKT activity. Merck Sharp & Dohme, Matthew A Leff, Yong Zhao, David A Muthard, May 1, 2012: US08168652 (3 worldwide citation)

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


3

4
Kevin Rodzinak
Jeannie M Arruda, Brian T Campbell, Nicholas D P Cosford, Jacob M Hoffman, Essa H Hu, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Tony Siu, Brian A Stearns, Lida R Tehrani, Mark T Bilodeau, Peter J Manley: Inhibitors of Akt activity. Merck Sharp & Dohme, Matthew A Leff, David A Muthard, March 22, 2011: US07910561 (1 worldwide citation)

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer ...


5
Mark T Bilodeau, Mark E Duggan, John C Hartnett, Craig W Lindsley, Peter J Manley, Zhicai Wu, Zhijian Zhao: Inhibitors of Akt activity. Merck & Co, Matthew A Leff, David A Muthard, May 29, 2007: US07223738 (23 worldwide citation)

The present invention is directed to compounds comprising a 2,3-diphenylquinoxaline moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating canc ...


6
Stanley F Barnett, Samuel L Graham, David C Remy: Inhibitors of Akt activity. Merck & Co, Mark R Daniel, Matthew A Leff, April 25, 2006: US07034026 (22 worldwide citation)

The present invention is directed to compounds comprising a 2,3-diphenylquinoxaline moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating canc ...


7
Mark T Bilodeau, Peter C Chua, Nicholas D P Cosford, Jacob M Hoffman, Johnny Yasuo Nagasawa: Inhibitors of Akt activity. Merck Sharp & Dohme, Matthew A Leff, David A Muthard, February 2, 2010: US07655649 (9 worldwide citation)

The present invention is directed to compounds which contain substituted pyridazines and pyrimidines moieties which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and method ...


8
Chandra Vargeese, Peter Haeberli, Weimin Wang, Tongqian Chen: Conjugates and compositions for cellular delivery. Sirna Therapeutics, Matthew A Leff, David A Muthard, June 21, 2011: US07964578 (8 worldwide citation)

This invention features conjugates, degradable linkers, compositions, methods of synthesis, and applications thereof, including cholesterol, folate, galactose, galactosamine, N-acetyl galactosamine, PEG, phospholipid, peptide and human serum albumin (HSA) derived conjugates of biologically active co ...


9
Christopher J Dinsmore, Jeffrey M Bergman, Samuel L Graham, Diem N Nguyen, Gerald E Stokker, Theresa M Williams, C Blair Zartman: Inhibitors of prenyl-protein transferase. Merck & Co, Matthew A Leff, Mark R Daniel, May 13, 2003: US06562823 (7 worldwide citation)

The present invention is directed to peptidomimetic piperazine-containing macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and ...


10
William Robert Carling, Jose Luis Castro Pineiro, Kevin William Moore: Inhibitors of Akt activity. Merck & Co, Matthew A Leff, Mark R Daniel, November 1, 2005: US06960584 (7 worldwide citation)

The present invention is directed to compounds comprising a triazolo[4,3-b]pyridazine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating ca ...



Click the thumbnails below to visualize the patent trend.